Drug Treatment of Parkinson’s Disease
InPharmaPublished 1 September 1984
E.N.H. Jansen
Citations9
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
The symptoms of idiopathic Parkinson’s disease are due mainly to progressive degeneration of the dopaminergic nigro-striatal pathways in the brain. The drugs which can help fall into five categories: dopamine replacement, using dopa with a decarboxylase inhibitor; a dopamine agonist, bromocriptine; 1 selegiline, recently introduced, which inhibits monoamine oxidase B; anticholinergic drugs; and amantadine. 2 This article discusses recent ideas about the management of Parkinson’s disease, particularly about levodopa dosage, bromocriptine and selegiline.
Keywords
ChemistryMedicineNeuroscience
The Lancet"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
662 Citations1976C. D. Marsden, J. D. Parkes
"Yo-yo-ing", which is the severest form of such fluctuation in mobility and dyskinesias, may represent the sum of these disorders.
QJMThe Impact of Treatment with Levodopa on Parkinson's Disease
164 Citations1980Kenneth Shaw, Andrew J. Lees +1 more
The progress of 178 patients with Parkinson's disease who began treatment with levodopa between November 1969 and December 1972 is reviewed after six years, and 32 per cent of the patients had unequivocal dementia.
Acta Neurologica ScandinavicaBRAIN ACETYLCHOLINESTERASE IN PARKINSON'S DISEASE
29 Citations2009U. K. Rinne, Paavo Riekkinen +2 more
It is concluded that the cholinergic mechanisms in the extrapyramidal system of parkinsonian brain are not so severely affected as the dopaminergic ones leading to relative and functional Cholinergic dominance.
Movement DisordersProblems in Parkinson's disease
24 Citations1981C. D. Marsden, Stanley Fahn
Most patients with Parkinson's disease or postencephalitic Parkinsonism show some response to levodopa, and those developing mental changes already have early or obvious dementia.
Blue books of neurologyDementia in Parkinson's Disease
14 Citations2009David J. Burn
This chapter highlights the areas of deficiency related to PD and the relationship between Parkinson's disease (PD) dementia and dementia with Lewy bodies (DLB), and the clinical diagnostic criteria for levels of “probable” and “possible” PDD are proposed.